What is Cymbalta?

Preparation of Cymbalta is a medicine containing the active substance Duloxetine. It is available in the form of enteric hard capsules (30 mg: white, blue, 60 mg: green-blue). The term "gastro-resistant hard" means that the capsule passes through the stomach without dissolving until the reach the intestines. This prevents the destruction of the active substance by gastric acid.
To what purpose, the preparation Cymbalta?

Preparation Cymbalta is used to treat adults with the Cymbalta following diseases:

* Episodes of major depression,
* Pain associated with diabetic peripheral neuropathy (nerve damage to the limbs, which may occur in patients with diabetes).

The medicine is available only on prescription.
How to use Cymbalta preparation?

The recommended dose of Cymbalta is 60 mg once a day, during meals or between meals.
When medication is used to treat depression, the response usually is observed after two - Cymbalta four weeks, but it is recommended to continue treatment for several months in order to avoid the recurrence of disease.
In the treatment of pain associated with diabetic neuropathy, some patients may require a higher dose of 120 mg per day, and response to treatment should be assessed two months after starting treatment. If the treatment is effective, an assessment should be repeated at least every three months.
Caution should be exercised in the use Cymbalta of Cymbalta with elderly patients, particularly at higher doses. Of Cymbalta should not be used in patients who suffered from liver dysfunction. In the event of termination of treatment, you should gradually reduce the dose of the preparation.
Cymbalta How does Cymbalta?

The active substance in the preparation Cymbalta, duloksetyna, is an inhibitor of reverse serotonin uptake and adrenaline. It works by preventing the neurotransmitters 5-capture hydroksytryptaminy (serotonin) and noradrenaline by the nerve cells in the brain and spinal cord. Neurotransmitters are chemicals capable of communication between nerve cells. Blocking the return of their capture Duloxetine increases the level of communication between nerve cells. Since Cymbalta neurotransmitters are involved in maintaining a good mood and reducing pain feeling, capture their feedback inhibition may alleviate symptoms of depression and pain in neuropathy.

Cymbalta was studied as a preparation?

In the treatment of major depression Cymbalta preparation was evaluated in seven major studies involving 2 256 patients. In six of these studies evaluated the effectiveness of Cymbalta in the treatment of depression, and one study evaluated the performance in preventing the resurgence. In Cymbalta studies on the effectiveness of treatment with four different doses of Cymbalta compared the effectiveness of a placebo (inactive treatment) for up to six months. In some studies comparing the effectiveness of Cymbalta with a performance paroxetine (another anti-depressant drug). The primary measure of efficacy was the change in severity of depressive symptoms measured by the 17-components Hamilton Depression Scale (HAM-D). The study compared the effectiveness of relapse Cymbalta and placebo for six Cymbalta months in patients with initial response to treatment with Cymbalta, assessing the time to recurrence of symptoms.
In the treatment of pain associated with neuropathy Cymbalta preparation was assessed in two 12-week study involving 809 adults with diabetes in whom pain occurred daily for at least the past six months, but who do not have a large depression. The effectiveness of three different doses of Cymbalta compared with placebo efficacy. The primary measure of Cymbalta efficacy was the change in the degree of severity of pain each week, recorded by patients on the 11-point scale in daily note.
What benefit has been observed in studies Cymbalta?

In the treatment of major depression Cymbalta preparation was evaluated in seven major studies involving 2 256 patients. In six of these studies evaluated the effectiveness of Cymbalta in the treatment of depression, and one study evaluated the performance in preventing the resurgence. In Cymbalta studies on the effectiveness of treatment with four different doses of Cymbalta compared the effectiveness of a placebo (inactive treatment) for up to six months. In some studies comparing the effectiveness of Cymbalta with a performance paroxetine (another anti-depressant drug). The primary measure of efficacy was the change in severity of depressive symptoms measured by the 17-components Hamilton Depression Scale (HAM-D). The study compared the effectiveness of relapse Cymbalta and placebo for six Cymbalta months in patients with initial response to treatment with Cymbalta, assessing the time to recurrence of symptoms.
In the treatment of pain associated with neuropathy Cymbalta preparation was assessed in two 12-week study involving 809 adults with diabetes in whom pain occurred daily for at least the past six months, but who do not have a large depression. The effectiveness of three different doses of Cymbalta compared with placebo efficacy. The primary measure of Cymbalta efficacy was the change in the degree of severity of pain each week, recorded by patients on the 11-point scale in daily note.

What is the risk associated with the use of Cymbalta?

The most common side effects associated with the use of Cymbalta (observed more than 1 patient at 10) are insomnia (difficulty falling asleep), headache, drowsiness, nausea, dry mouth and diarrhea. Most of these activities had little or moderate severity, began at an Cymbalta early stage of treatment, and their severity decreased with continuing treatment. The full list of side effects reported with Cymbalta is in a leaflet for the patient.
Of Cymbalta should not be given to persons who may be hypersensitive (allergic) to Duloxetine or any other ingredients. Of Cymbalta should not be used in combination with inhibitors (another type of antidepressants), fluwoksamin (another anti-depressant drug) and ciprofloxacin or enoksacyn (type of antibiotics). Cymbalta is Cymbalta not a preparation should also be used in patients with certain types of liver diseases, as well as in patients with severe kidney disease. Do not start treatment in patients with poorly controlled hypertension (high blood pressure) due to the risk of breakthrough high pressure(sudden, dangerous increase in blood pressure).
As with other antidepressants, patients taking Cymbalta preparation were isolated cases of suicidal thoughts and behavior, especially during the first few weeks of treatment Cymbalta of depression. Patients taking Cymbalta preparation in which, at any time there are disturbing thoughts or experiences, they should immediately report it to the doctor.
Why Cymbalta approved product?

The Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits from the use of Cymbalta outweigh the risks associated with major episodes of depression treatment and pain in diabetic peripheral neuropathy in adults. The Committee recommended the granting of authorization to market Cymbalta preparation.